BY AND BETWEENProduct Acquisition Agreement • February 7th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
ContractProduct Acquisition Agreement • August 15th, 2006 • Barr Pharmaceuticals Inc • Pharmaceutical preparations
Barr and Shire Sign Three Agreements: A Product Acquisition Agreement for ADDERALL®; A Product Development Agreement; and A Settlement and License Agreement for ADDERALL XR®
TERMS AND CONDITIONS PRODUCT ACQUISITIONProduct Acquisition Agreement • November 28th, 2016
These Terms and Conditions (as amended, restated or otherwise modified from time to time, the “Terms”), together with the terms of an applicable Purchase Order executed by the parties (each, a “Purchase Order”; together with the Terms, collectively, the “Agreement”) governs Your provision of the Products (defined below) to Sturdivant Ventures, LLC d/b/a Landseye, a California limited liability company (“Landseye). This Agreement supersede all prior agreements, proposals and discussions among the parties with respect to the supply and purchase of the Products. To the extent there is a conflict between this Agreement and any Purchase Order or other document, this Agreement shall prevail.
PRODUCT ACQUISITION AGREEMENT by and between VALEANT PHARMACEUTICALS NORTH AMERICA (as buyer) and INTERMUNE, INC. (as seller) November 28, 2005Product Acquisition Agreement • August 8th, 2006 • Intermune Inc • Pharmaceutical preparations • Delaware
This PRODUCT ACQUISITION AGREEMENT (as amended from time to time, the “Agreement”), dated November 28, 2005 (the “Execution Date”), is made and entered into by and between VALEANT PHARMACEUTICALS NORTH AMERICA, a Delaware corporation (the “Buyer”), and INTERMUNE, INC., a Delaware corporation (the “Seller”). Buyer and Seller are sometimes collectively referred to herein as the “Parties” and separately as a “Party.”
AMPHOTEC®/AMPHOCIL® PRODUCT ACQUISITION AGREEMENT BETWEEN ALZA CORPORATION AND INTERMUNE PHARMACEUTICALS, INC.Product Acquisition Agreement • May 15th, 2001 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations • California
This Product Acquisition Agreement (the "Agreement") is made effective as of the 2nd day of January, 2001 between ALZA Corporation ("ALZA"), a Delaware corporation and InterMune Pharmaceuticals, Inc., a Delaware corporation ("InterMune").
Valeant Pharmaceuticals North America One Enterprise Aliso Viejo, CA 92656Product Acquisition Agreement • March 14th, 2008 • Intermune Inc • Pharmaceutical preparations
Re: Product Acquisition Agreement (the “Product Acquisition Agreement”) dated as of November 28, 2005 by and between InterMune, Inc. (“Seller”) and Valeant Pharmaceuticals North America (“Buyer”) – Transition Trademark License
CONFIDENTIAL TREATMENT REQUESTED Portions of this exhibit indicated by “[***]” have been omitted, and such omitted portions have been filed separately with the Securities and Exchange Commission (SEC). Confidential treatment has been requested with...Product Acquisition Agreement • October 1st, 2014 • Akorn Inc • Pharmaceutical preparations • New York
This Product Acquisition Agreement (this “Agreement”) is entered into as of September 30, 2014, by and among Sunovion Pharmaceuticals Inc., a Delaware corporation (“Seller”), Oak Pharmaceuticals, Inc., a Delaware corporation (“Purchaser”) and Akorn, Inc., a Louisiana corporation (“Parent”).
